Adagio Medical shares surge 15.21% intraday after appointing seasoned executives to accelerate ULTC commercialization.

Adagio Medical surged 15.21% intraday following the announcement of two key executive appointments to accelerate commercialization of its Ultra-Low Temperature Cardiac Ablation (ULTC) technology. Marie-Claude Jacques, a seasoned leader with a track record of scaling disruptive medical technologies at Baylis Medical and Boston Scientific, was named Senior Vice President, Global Sales, while Antwan Gipson, a 20-year veteran in manufacturing and operations for medical devices, joined as Senior Vice President, Manufacturing & Operations. The appointments underscore Adagio’s readiness to launch its vCLAS Cryoablation System, which is undergoing pivotal U.S. trials for FDA approval and is already commercially available in Europe. The hires signal strengthened leadership in sales execution and scalable production, critical for navigating regulatory pathways and market adoption. Todd Usen, CEO, emphasized the strategic importance of these roles in achieving 2026 commercialization goals, aligning investor confidence with the company’s growth trajectory.